Cargando…
MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and SRC mRNA were highly expressed by a wide range of these cancers, su...
Autores principales: | Castillo, Lesley, Young, Adelaide I. J., Mawson, Amanda, Schafranek, Pia, Steinmann, Angela M., Nessem, Danielle, Parkin, Ashleigh, Johns, Amber, Chou, Angela, Law, Andrew M. K., Lucas, Morghan C., Murphy, Kendelle J., Deng, Niantao, Gallego-Ortega, David, Caldon, Catherine E., Timpson, Paul, Pajic, Marina, Ormandy, Christopher J., Oakes, Samantha R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033042/ https://www.ncbi.nlm.nih.gov/pubmed/31735913 http://dx.doi.org/10.1038/s41388-019-1091-0 |
Ejemplares similares
-
MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib
por: Young, Adelaide I. J., et al.
Publicado: (2016) -
Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion
por: Young, Adelaide IJ, et al.
Publicado: (2017) -
Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy
por: Parkin, Ashleigh, et al.
Publicado: (2019) -
The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018) -
Systematic functional identification of cancer multi-drug resistance genes
por: Lau, Man-Tat, et al.
Publicado: (2020)